stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) Current ratio
Summit Therapeutics PLC's current ratio at the end of the quarter to 30 June 2026 was 7.0×, down 2.9× from fiscal 2025 (9.9×). Over the past ten years it has ranged from 1.6× (fiscal 2018) to 16.9× (fiscal 2022); the current reading is higher than 87% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 9.9× | (2.82%) |
| FY2024 | 10.2× | 9.22% |
| FY2023 | 9.3× | (45.09%) |
| FY2022 | 16.9× | 345.87% |
| FY2021 | 3.8× | (13.84%) |
| FY2020 | 4.4× | (23.79%) |
| FY2019 | 5.8× | 59.26% |
| FY2019 | 3.6× | 130.36% |
| FY2018 | 1.6× | (16.79%) |
| FY2018 | 1.9× | (38.08%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 7.0× | (6.04%) |
| Mar 2026 | 7.4× | (24.96%) |
| Dec 2025 | 9.9× | 159.98% |
| Sep 2025 | 3.8× | (25.95%) |
| 44 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| KYMR Kymera Therapeutics, Inc. compare | 11.1× |
| SMMT Summit Therapeutics PLC | 7.0× |
| PCVX Vaxcyte, Inc. compare | 5.7× |
| TECH Bio-Techne Corp compare | 4.5× |
| HALO Halozyme Therapeutics, Inc. compare | 3.9× |
| ASND Ascendis Pharma A/S compare | 3.0× |
| BMRN BioMarin Pharmaceutical Inc. compare | 2.4× |
| BBIO BridgeBio Pharma, Inc. compare | 2.1× |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.8× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement